I searched MEDLINE and the Cochrane Database of Systematic Reviews for articles published between Jan 1, 2005, and Aug 31, 2015, and reviewed original publications, review articles, and abstracts in published in English. Additionally, I searched my personal literature libraries. I used the following search terms: “chronic kidney disease”, “dialysis patients”, “end-stage renal disease”, “ESRD”, “angiotensin-converting enzyme inhibitor”, “ACE-I”, “angiotensin II receptor blocker”, “ARB”,
ReviewReduction of cardiovascular risk in chronic kidney disease by mineralocorticoid receptor antagonism
Introduction
Cardiovascular disease is the leading cause of death and morbidity in people with chronic kidney disease.1, 2 The Global Burden of Disease study identified chronic kidney failure as one of the three causes of death with the greatest increase from 1990 to 2010.1 Patients with chronic kidney disease have up to a three to five times increased risk of cardiovascular events,1 and cardiovascular disease is the most common cause of mortality and morbidity in these patients.
The rates of cardiovascular events and mortality consistently increase as kidney function deteriorates.3 Patients on dialysis have mortality rates up to 40 times higher than the general population,4 with cardiovascular disease causing up to 50% of these deaths.5 The increase in cardiovascular risk for a young patient (aged 25–34 years) with end-stage renal disease on dialysis is 100–1000 times greater than for age-matched healthy people, and this falls to about ten times for patients older than 85 years.6
Chronic kidney disease is common worldwide, affecting up to 16% of the population.2, 7, 8, 9 As a consequence of the increasing prevalence of this condition and of dialysis-dependent end-stage renal disease, the number of people at high risk of cardiovascular events will increase, with growing demands on health services worldwide. These observations emphasise the need to define and establish therapeutic initiatives to modify cardiovascular risk. Addressing this unmet need is a clinical priority.
In this Review, I first discuss the pathophysiology of cardiovascular disease in chronic kidney disease, and briefly consider recent global clinical trials designed to reduce cardiovascular outcomes in patients with chronic kidney disease. I then discuss the several studies that have clearly shown beneficial effects of mineralocorticoid receptor (MR) antagonists on cardiovascular outcomes in patients with chronic heart failure and post-myocardial infarction without concomitant kidney disease. Finally, I argue that, despite differences in the pathophysiology and clinical features of cardiovascular disease in patients with and without chronic kidney disease, MR antagonists might also be effective in attenuating cardiovascular events in patients with chronic kidney disease.
Section snippets
Cardiovascular disease in chronic kidney disease
Cardiovascular disease in chronic kidney disease can be attributed to two distinct but overlapping pathological processes—namely, atherosclerosis and arteriosclerosis.10 Although the risk of atherothrombotic events such as myocardial infarction is raised, arteriosclerosis is the predominant pathophysiological process, which involves fibrosis and thickening of the medial arterial layer. The subsequent increase in arterial stiffness leads to left ventricular hypertrophy and fibrosis, thereby
Cardiovascular risk markers and treatment for cardiovascular events in kidney disease
In chronic kidney disease established markers of cardiovascular disease, such as raised cholesterol19 and blood pressure,20 do not always have the same log-linear association with cardiovascular events as in the general population. In end-stage renal disease there is an inverse association between cardiovascular event rates and conventional risk factors such as total cholesterol, obesity, and even blood pressure. These paradoxical associations might, at least in part, be explained by reverse
Aldosterone and MR antagonism: a rational approach to reduce cardiovascular risk
It is now realised that the traditional concepts governing aldosterone and the MR are wrong:42 angiotensin is not the major driver of aldosterone secretion; aldosterone is merely one of several physiological ligands for the MR; and, although the sodium-retaining effects of aldosterone are clearly relevant in maintaining volume homoeostasis in the setting of hypovolaemia, aldosterone increases blood pressure mainly by actions on the vasculature and CNS.
The figure and panel summarise the new
Risks of available MR antagonists
Pharmacological differences between spironolactone and eplerenone include lower affinity of eplerenone for progesterone, androgen, and glucocorticoid receptors, and the presence of longacting metabolites for spironolactone.74, 75
Both agents produce dose-dependent increases in potassium concentrations. However, caution is needed when comparing the rates of hyperkalaemia between spironolactone and eplerenone. Struthers and colleagues74 speculated that the extended half-life of the active
Aldosterone and cardiovascular events in patients on haemodialysis
When end-stage renal disease is reached, the prevalence of cardiac comorbidities is extremely high.4, 5 Several investigators have assessed whether increased concentrations of aldosterone correlate with these dire cardiovascular outcomes. In the CRIC study, Deo and colleagues86 reported that in participants with chronic kidney disease, higher aldosterone concentrations were independently associated with the development of congestive heart failure, but not with death, end-stage renal disease, or
Evidence from trials of MR antagonists in heart failure
The evidence presented above suggests that renal disease is associated with a high risk of cardiovascular disease and that aldosterone concentrations and MR activation are increased in patients with renal disease. Additionally, it suggests that activation of these systems can contribute to the pathophysiological mechanisms behind increased cardiovascular disease in these patients, and that blockade of these systems prevents cardiovascular disease morbidity and mortality in other cardiovascular
Continuing and recently completed MR antagonist clinical trials
Of the eight MR antagonist clinical trials, three (PHASE,94 MiREnDa,95 and ALCHEMIST [NCT018448639]) are in patients with end-stage renal disease undergoing dialysis, three (ARTS-DN,73 FIGARO-DKD [NCT02540993], and FIDELIO-DKD [NCT02545049]) are in patients with chronic kidney disease, and two (ARTS-HF85 and FINESSE-HF) are in patients with chronic heart failure (table). The pilot study in patients with end-stage renal disease (PHASE)94 is now complete and has shown the safety of eplerenone
Hyperkalaemia associated with MR antagonist treatment
Most clinicians are reluctant to prescribe MR antagonists in patients with chronic kidney disease, and in patients with end-stage renal disease on haemodialysis, because of the risk of hyperkalaemia.47, 97, 98 MR antagonists are contraindicated in patients with an eGFR of less than 30 mL/min/1·73m2, including patients on haemodialysis. A recent study99 that did an in-depth analysis of de-identified medical records from a large database of electronic health records (initially screening 1·7
Conclusion
Enhanced MR activation complicates the clinical course of chronic kidney disease and end-stage renal disease, and contributes to progression of disease, maintenance of hypertension, and importantly associated cardiovascular complications.49, 50, 51, 52, 53, 54, 55, 57 Compelling evidence from clinical trials in the general population without chronic kidney disease has shown that treatment with MR antagonists confers a morbidity and mortality advantage for patients with cardiovascular disorders
Search strategy and selection criteria
References (103)
- et al.
Epidemiology, contributors to, and clinical trials of mortality risk in chronic kidney failure
Lancet
(2014) - et al.
Cardiovascular disease in patients with chronic kidney disease
- et al.
Clinical epidemiology of cardiovascular disease in chronic renal disease
Am J Kidney Dis
(1998) - et al.
Endothelial dysfunction and cardiovascular disease in early-stage chronic kidney disease: cause or association?
Atherosclerosis
(2012) - et al.
Vascular calcification in chronic kidney disease: new developments in drug therapy
Kidney Int
(2007) - et al.
Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients
Kidney Int
(2003) - et al.
The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial
Lancet
(2011) - et al.
Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial
J Am Coll Cardiol
(2003) - et al.
Effects of telmisartan added to angiotensin-converting enzyme inhibitors on mortality and morbidity in hemodialysis patients with chronic heart failure a double-blind, placebo-controlled trial
J Am Coll Cardiol
(2010) - et al.
Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinopril and implications for future studies
Kidney Int
(2006)